Point72 Hong Kong LTD Blueprint Medicines Corp Transaction History

Point72 Hong Kong LTD

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $284,416 - $363,216	3,339 New	3,339 $359,000
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $258,337 - $402,019	5,174 Added 4881.13%	5,280 $348,000
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $145,052 - $224,971	-3,207 Reduced 96.8%	106 $5,000
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $179,233 - $364,695	3,313 New	3,313 $212,000
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $74,080 - $91,168	-786 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $63,650 - $86,043	786 New	786 $81,000
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $46,592 - $62,986	-506 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $28,905 - $40,324	435 Added 612.68%	506 $47,000
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $20,095 - $27,903	-352 Reduced 83.22%	71 $6,000
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $20,350 - $34,779	423 New	423 $25,000
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $92,354 - $114,304	-1,384 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $100,893 - $140,351	1,384 New	1,384 $102,000
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $19,868 - $32,377	-436 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $25,684 - $34,147	436 New	436 $34,000
Q1 2018 May 15, 2018	SELL	$73.28 - $102.95 $73 - $102	-1 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $23,025 - $32,325	-366 Reduced 99.73%	1 $0
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $15,549 - $25,568	367	367 $26,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.65B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.